Xerostomia Therapeutics Market Size, Share & Trends Analysis Report By Type (OTC, Prescription), By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices), By Region, And Segment Forecasts, 2018 - 2025

Industry Insights

The global xerostomia therapeutics market size was estimated at USD 602.3 million in 2016. Increasing adoption of chemotherapy and radiotherapy in cancer treatment coupled with rising use of prescribed medications are some of the key factors expected to boost the xerostomia therapeutics market.

Chemotherapy and radiation damage the salivary gland and cause dry mouth. Chemotherapy is the most common form of treatment to cancer patients provided by oncologists and medical practitioners. According to the Centers for Disease Control & Prevention (CDC), every year about 650,000 cancer patients receive chemotherapy in an outpatient oncology clinic.

The American Cancer Society estimates that 3.5 million women live with breast cancer in the U.S., as of January 1, 2016. Among women with stage IV breast cancer, 48% receive radiation and/or chemotherapy.

Easy availability of cost-effective medications is one of the key drivers of the market. Products include mouthwashes & oral rinses, saliva substitute gels, sugar-free chewing gums, lozenges, toothpastes & oral-adhering discs, patches, and melts. The price of these products range from USD 10 to 90 and the reimbursement policies of these products are favorable. For instance, Ontario Ministry of Health and Long-Term Care provides funds to patients with radiation-induced xerostomia undergoing treatment with drug, Salagen, under the Exceptional Access Program (EAP).

Increase in use of prescription medications is expected to positively affect the market growth. According to National Institute of Dental and Craniofacial Research, more than 400 medications may cause xerostomia.

Prescription medicines such as antidepressants, antihypertensives, sedatives, antiparkinson, antiemetics, and antipsychotics affect the salivary gland and cause xerostomia. Increasing prevalence of diseases such as Parkinson’s disease, hypertension, diabetes, and HIV lead to use of prescription drugs, thus causing the condition of dry mouth.

Type Insights

On the basis of type, the market is categorized into Over-the-Counter (OTC) and prescription. The OTC segment in terms of value accounted for the largest share in 2016 and is expected to grow at a lucrative CAGR over the forecast period.

The dominance is owing to its wide variety & availability, safety & efficacy, availability of limited branded drugs, and low pricing of products. OTC products are the first-line treatment for xerostomia.

Product Insights

Based on product, the market is categorized into salivary stimulants, salivary substitutes, and dentifrices. The dentifrices segment dominated the overall market in terms of revenue in 2016, owing to its effectiveness, availability, affordability, and higher adoption among end users.

Salivary stimulants are expected to witness the fastest growth over the forecast period. Salivary stimulants are available in various forms such as mints, sugar-free chewing gums, sprays, and lozenges. A wide range of substitutes for each product is easily available and accessible to patients. All the aforementioned factors are expected to contribute to the growth of the segment.

Regional Insights

North America dominated the regional segment with the largest share of revenue in 2016 followed by Europe. Key factors contributing toward dominance are increasing prevalence of xerostomia and other dry mouth associated diseases such as Sjogren’s syndrome, rheumatoid arthritis, and HIV coupled with increase in dry mouth awareness initiatives. For instance, Sjogren Syndrome Foundation of the U.S. is responsible for conducting awareness and supporting patients with xerostomia in the U.S. and Canada.

However, Asia Pacific is expected to grow with a lucrative CAGR over the forecast period due to growing healthcare expenditure, increase in initiatives for raising awareness, and rising prevalence of diseases such as diabetes, HIV, cancer, & Parkinson’s disease that cause dry mouth conditions. Asia Pacific is projected to grow with significant CAGR of 4.2 % over the forecast period.

Competitive Insights

Some of the key players dominating the xerostomia therapeutics market are GlaxoSmithKline plc; Church & Dwight Co., Inc.; Colgate-Palmolive Company; Hikma Pharmaceuticals PLC; Pendopharm; Sun Pharmaceuticals Industries Ltd.; Lupin Pharmaceuticals, Inc.; Pfizer, Inc.; Parnell Pharmaceuticals, Inc.; Acacia Pharma; and OraCoat.

Key players focus on the development of their product portfolio, acquisition of emerging players, and distribution agreements to increase their geographical presence. For instance, Hikma Pharmaceuticals acquired Roxane Laboratories, a part of West-Ward Pharmaceuticals Corp, to enhance their product portfolio in the oral care segment.

Report Scope

Segments covered in the report

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2016 to 2025. For the purpose of this study, Grand View Research has segmented the global xerostomia therapeutics market on the basis of type, product, and region:

• Type Outlook (Market Revenue in USD Million, 2014 - 2025)

  • OTC

  • Prescription

• Product Outlook (Market Revenue in USD Million, 2014 - 2025)

  • Salivary Stimulants

  • Salivary Substitutes

  • Dentifrices

• Regional Outlook (Revenue, USD Million, 2014 - 2025)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

  • Asia Pacific

    • China

    • Japan

    • India

  • Latin America

    • Brazil

    • Mexico

  • Middle East & Africa

    • South Africa